{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:23:06Z","timestamp":1785410586992,"version":"3.56.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-025-04419-4","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T10:00:38Z","timestamp":1763546438000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety analysis of D-TACE combined with lenvatinib in the treatment of hepatocellular carcinoma refractory to C-TACE"],"prefix":"10.1186","volume":"25","author":[{"given":"Haohao","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuansheng","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangwen","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"issue":"11","key":"4419_CR1","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1080\/17474124.2021.1991792","volume":"15","author":"P Konyn","year":"2021","unstructured":"Konyn P, Ahmed A, Kim D. Current epidemiology in hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol. 2021;15(11):1295\u2013307. https:\/\/doi.org\/10.1080\/17474124.2021.1991792.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"1","key":"4419_CR2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00261-017-1209-1","volume":"43","author":"A Tang","year":"2018","unstructured":"Tang A, Hallouch O, Chernyak V, Kamaya A, Sirlin CB. Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis. Abdom Radiol (NY). 2018;43(1):13\u201325. https:\/\/doi.org\/10.1007\/s00261-017-1209-1.","journal-title":"Abdom Radiol (NY)"},{"key":"4419_CR3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2147\/HMER.S16316","volume":"4","author":"R Dhanasekaran","year":"2012","unstructured":"Dhanasekaran R, Limaye A, Cabrera R. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics. Hepat Med. 2012;4:19\u201337. https:\/\/doi.org\/10.2147\/HMER.S16316. PMID: 24367230; PMCID: PMC3846594.","journal-title":"Hepat Med"},{"issue":"3","key":"4419_CR4","doi-asserted-by":"publisher","first-page":"155","DOI":"10.5582\/bst.2021.01091","volume":"15","author":"H Zhou","year":"2021","unstructured":"Zhou H, Song T. Conversion therapy and maintenance therapy for primary hepatocellular carcinoma. Biosci Trends. 2021;15(3):155\u201360. https:\/\/doi.org\/10.5582\/bst.2021.01091.","journal-title":"Biosci Trends"},{"key":"4419_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.acr.2020.10.001","volume":"149","author":"S Chidambaranathan-Reghupaty","year":"2021","unstructured":"Chidambaranathan-Reghupaty S, Fisher PB, Sarkar D. Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification. Adv Cancer Res. 2021;149:1\u201361. https:\/\/doi.org\/10.1016\/bs.acr.2020.10.001. Epub 2020 Nov 28. PMID: 33579421; PMCID: PMC8796122.","journal-title":"Adv Cancer Res"},{"issue":"11","key":"4419_CR6","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1055\/s-2007-963285","volume":"179","author":"TJ Vogl","year":"2007","unstructured":"Vogl TJ, Zangos S, Balzer JO, Nabil M, Rao P, Eichler K, et al. Transarterielle Chemoembolisation (TACE) des hepatozellul\u00e4ren Karzinoms: Technik, Indikationsstellung und Ergebnisse [Transarterial chemoembolization (TACE) in hepatocellular carcinoma: technique, indication and results]. Rofo. 2007;179(11):1113-26. German. https:\/\/doi.org\/10.1055\/s-2007-963285. PMID: 17948190.","journal-title":"Rofo"},{"issue":"7","key":"4419_CR7","doi-asserted-by":"publisher","first-page":"e41943","DOI":"10.7759\/cureus.41943","volume":"15","author":"J Ayyub","year":"2023","unstructured":"Ayyub J, Dabhi KN, Gohil NV, Tanveer N, Hussein S, Pingili S, et al. Evaluation of the safety and efficacy of conventional transarterial chemoembolization (cTACE) and Drug-Eluting bead (DEB)-TACE in the management of unresectable hepatocellular carcinoma: A systematic review. Cureus. 2023;15(7):e41943. https:\/\/doi.org\/10.7759\/cureus.41943. PMID: 37465089; PMCID: PMC10351914.","journal-title":"Cureus"},{"issue":"28","key":"4419_CR8","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.2217\/fon-2018-0136","volume":"14","author":"F Melchiorre","year":"2018","unstructured":"Melchiorre F, Patella F, Pescatori L, Pesapane F, Fumarola E, Biondetti P, et al. DEB-TACE: a standard review. Future Oncol. 2018;14(28):2969\u201384. https:\/\/doi.org\/10.2217\/fon-2018-0136.","journal-title":"Future Oncol"},{"issue":"3","key":"4419_CR9","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s00117-022-00972-1","volume":"62","author":"P Huppert","year":"2022","unstructured":"Huppert P. Transarterielle chemoembolisation des hepatozellul\u00e4ren Karzinoms [Transarterial chemoembolization of hepatocellular carcinoma]. Radiologe. 2022;62(3):225\u201333. https:\/\/doi.org\/10.1007\/s00117-022-00972-1. German. doi:.","journal-title":"Radiologe"},{"issue":"3","key":"4419_CR10","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1159\/000327577","volume":"29","author":"M Kudo","year":"2011","unstructured":"Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O, et al. Management of hepatocellular carcinoma in Japan: consensus-based clinical practice guidelines proposed by the Japan society of hepatology (JSH) 2010 updated version. Dig Dis. 2011;29(3):339\u201364. https:\/\/doi.org\/10.1159\/000327577.","journal-title":"Dig Dis"},{"issue":"Suppl 1","key":"4419_CR11","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1159\/000368142","volume":"87","author":"M Kudo","year":"2014","unstructured":"Kudo M, Matsui O, Izumi N, Kadoya M, Okusaka T, Miyayama S, et al. Transarterial chemoembolization failure\/refractoriness: JSH-LCSGJ criteria 2014 update. Oncology. 2014;87(Suppl 1):22\u201331. https:\/\/doi.org\/10.1159\/000368142.","journal-title":"Oncology"},{"issue":"4","key":"4419_CR12","doi-asserted-by":"publisher","first-page":"740","DOI":"10.14218\/JCTH.2021.00336","volume":"10","author":"S Zhang","year":"2022","unstructured":"Zhang S, Wang WS, Zhong BY, Ni CF. Subsequent treatment after transarterial chemoembolization failure\/refractoriness: a review based on published evidence. J Clin Transl Hepatol. 2022;10(4):740\u20137. https:\/\/doi.org\/10.14218\/JCTH.2021.00336.","journal-title":"J Clin Transl Hepatol"},{"issue":"3","key":"4419_CR13","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1148\/radiol.211806","volume":"303","author":"E Dhondt","year":"2022","unstructured":"Dhondt E, Lambert B, Hermie L, Huyck L, Vanlangenhove P, Geerts A, et al. 90Y radioembolization versus drug-eluting bead chemoembolization for unresectable hepatocellular carcinoma: results from the TRACE phase II randomized controlled trial. Radiology. 2022;303(3):699\u2013710. https:\/\/doi.org\/10.1148\/radiol.211806.","journal-title":"Radiology"},{"issue":"3","key":"4419_CR14","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s12029-020-00502-z","volume":"52","author":"RD Hirsch","year":"2021","unstructured":"Hirsch RD, Mills C, Sawhney R, Sood S, Bird V, Mishra G, et al. SIRT compared with DEB-TACE for hepatocellular carcinoma: a real-world study (the SITAR study). J Gastrointest Cancer. 2021;52(3):907\u201314. https:\/\/doi.org\/10.1007\/s12029-020-00502-z.","journal-title":"J Gastrointest Cancer"},{"issue":"6","key":"4419_CR15","doi-asserted-by":"publisher","first-page":"528","DOI":"10.4240\/wjgs.v14.i6.528","volume":"14","author":"S Zhang","year":"2022","unstructured":"Zhang S, Zhong BY, Zhang L, Wang WS, Ni CF. Transarterial chemoembolization failure\/refractoriness: a scientific concept or pseudo-proposition. World J Gastrointest Surg. 2022;14(6):528\u201337. https:\/\/doi.org\/10.4240\/wjgs.v14.i6.528.","journal-title":"World J Gastrointest Surg"},{"issue":"3","key":"4419_CR16","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.jhep.2006.10.020","volume":"46","author":"M Varela","year":"2007","unstructured":"Varela M, Real MI, Burrel M, Forner A, Sala M, Brunet M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol. 2007;46(3):474\u201381. https:\/\/doi.org\/10.1016\/j.jhep.2006.10.020.","journal-title":"J Hepatol"},{"issue":"8","key":"4419_CR17","first-page":"9562","volume":"13","author":"X Yang","year":"2021","unstructured":"Yang X, Li H, Liu J, Du C, He T, Luo X, et al. The short-term efficacy of DEB-TACE loaded with epirubicin and raltitrexed in the treatment of intermediate and advanced primary hepatocellular carcinoma. Am J Transl Res. 2021;13(8):9562\u20139. PMID: 34540079; PMCID: PMC8430112.","journal-title":"Am J Transl Res"},{"issue":"3","key":"4419_CR18","doi-asserted-by":"publisher","first-page":"101814","DOI":"10.1016\/j.clinre.2021.101814","volume":"46","author":"J Tang","year":"2022","unstructured":"Tang J, Huang Z, Xu J, Lv Q, Wang P. Drug-eluting bead transarterial chemoembolization (TACE) exhibits superior efficacy and equal tolerance to conventional TACE in hepatocellular carcinoma patients with conventional TACE history. Clin Res Hepatol Gastroenterol. 2022;46(3):101814. Epub 2021 Sep 28. PMID: 34597848.","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"4419_CR19","doi-asserted-by":"publisher","first-page":"153303381983075","DOI":"10.1177\/1533033819830751","volume":"18","author":"H Xiang","year":"2019","unstructured":"Xiang H, Long L, Yao Y, Fang Z, Zhang Z, Zhang Y. CalliSpheres Drug-Eluting bead transcatheter arterial chemoembolization presents with better efficacy and equal safety compared to conventional TACE in treating patients with hepatocellular carcinoma. Technol Cancer Res Treat. 2019;18:1533033819830751. PMID: 30862264; PMCID: PMC6416678.","journal-title":"Technol Cancer Res Treat"},{"issue":"6","key":"4419_CR20","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1007\/s11845-021-02851-5","volume":"191","author":"Z Wang","year":"2022","unstructured":"Wang Z, Mu K, Lv Y, Zhao L, Li B, Hao Y, et al. Efficacy, safety, and prognostic factors of drug-eluting beads transarterial chemoembolization using callispheres in treating huge hepatocellular carcinoma patients. Ir J Med Sci. 2022;191(6):2493\u20139. https:\/\/doi.org\/10.1007\/s11845-021-02851-5.","journal-title":"Ir J Med Sci"},{"issue":"4","key":"4419_CR21","doi-asserted-by":"publisher","first-page":"297","DOI":"10.14740\/jocmr2496w","volume":"8","author":"K Liu","year":"2016","unstructured":"Liu K, Min XL, Peng J, Yang K, Yang L, Zhang XM. The changes of HIF-1\u03b1 and VEGF expression after TACE in patients with hepatocellular carcinoma. J Clin Med Res. 2016;8(4):297\u2013302. https:\/\/doi.org\/10.14740\/jocmr2496w.","journal-title":"J Clin Med Res"},{"issue":"1","key":"4419_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-023-02961-7","volume":"21","author":"R Duan","year":"2023","unstructured":"Duan R, Gong F, Wang Y, Huang C, Wu J, Hu L, et al. Transarterial chemoembolization (TACE) plus tyrosine kinase inhibitors versus TACE in patients with hepatocellular carcinoma: a systematic review and meta-analysis. World J Surg Oncol. 2023;21(1):120. https:\/\/doi.org\/10.1186\/s12957-023-02961-7.","journal-title":"World J Surg Oncol"},{"issue":"15","key":"4419_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14153710","volume":"14","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Wu Y, Zheng T, Chen X, Chen G, Chen H, et al. Efficacy of transarterial chemoembolization combined with molecular targeted agents for unresectable hepatocellular carcinoma: a network meta-analysis. Cancers (Basel). 2022;14(15):3710. https:\/\/doi.org\/10.3390\/cancers14153710.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"4419_CR24","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.3390\/curroncol30010096","volume":"30","author":"J Deng","year":"2023","unstructured":"Deng J, Liao Z, Gao J. Efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors for hepatocellular carcinoma patients with portal vein tumor thrombus: a systematic review and meta-analysis. Curr Oncol. 2023;30(1):1243\u201354. https:\/\/doi.org\/10.3390\/curroncol30010096.","journal-title":"Curr Oncol"},{"issue":"10126","key":"4419_CR25","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163\u201373. https:\/\/doi.org\/10.1016\/S0140-6736(18)30207-1.","journal-title":"Lancet"},{"issue":"1","key":"4419_CR26","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1200\/JCO.22.00392","volume":"41","author":"Z Peng","year":"2023","unstructured":"Peng Z, Fan W, Zhu B, Wang G, Sun J, Xiao C, et al. Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: a phase III, randomized clinical trial (LAUNCH). J Clin Oncol. 2023;41(1):117\u201327. https:\/\/doi.org\/10.1200\/JCO.22.00392.","journal-title":"J Clin Oncol"},{"key":"4419_CR27","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ejrad.2018.01.025","volume":"101","author":"C Ayuso","year":"2018","unstructured":"Ayuso C, Rimola J, Vilana R, Burrel M, Darnell A, Garc\u00eda-Criado \u00c1, et al. Diagnosis and staging of hepatocellular carcinoma (HCC): current guidelines. Eur J Radiol. 2018;101:72\u201381. https:\/\/doi.org\/10.1016\/j.ejrad.2018.01.025.","journal-title":"Eur J Radiol"},{"issue":"5","key":"4419_CR28","doi-asserted-by":"publisher","first-page":"661","DOI":"10.21037\/hbsn-21-260","volume":"10","author":"J Lu","year":"2021","unstructured":"Lu J, Zhao M, Arai Y, Zhong BY, Zhu HD, Qi XL, International Society of Multidisciplinary Interventional Oncology (ISMIO), et al. Clinical practice of transarterial chemoembolization for hepatocellular carcinoma: consensus statement from an international expert panel of international society of multidisciplinary interventional oncology (ISMIO). Hepatobiliary Surg Nutr. 2021;10(5):661\u201371. https:\/\/doi.org\/10.21037\/hbsn-21-260. PMID: 34760969; PMCID: PMC8527415.","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"1","key":"4419_CR29","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3109\/03009734.2012.729104","volume":"118","author":"Y Sato","year":"2013","unstructured":"Sato Y, Watanabe H, Sone M, Onaya H, Sakamoto N, Osuga K, et al. Japan interventional radiology in oncology study Group-JIVROSG. Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602. Ups J Med Sci. 2013;118(1):16\u201322. Epub 2012 Nov 20. PMID: 23167460; PMCID: PMC3572665.","journal-title":"Ups J Med Sci"},{"issue":"1","key":"4419_CR30","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","volume":"112","author":"A Freites-Martinez","year":"2021","unstructured":"Freites-Martinez A, Santana N, Arias-Santiago S, Viera A. Using the common terminology criteria for adverse events (CTCAE - version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr (Engl Ed). 2021;112(1):90\u20132. https:\/\/doi.org\/10.1016\/j.ad.2019.05.009.","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"issue":"7","key":"4419_CR31","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1053\/j.gastro.2007.04.061","volume":"132():-.","author":"HB El-Serag","year":"2007","unstructured":"El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132():-.(7):2557\u201376. https:\/\/doi.org\/10.1053\/j.gastro.2007.04.061. PMID: 17570226.","journal-title":"Gastroenterology"},{"issue":"1","key":"4419_CR32","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"European Association for the Study of the Liver","year":"2018","unstructured":"European Association for the Study of the Liver, European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182\u2013236. https:\/\/doi.org\/10.1016\/j.jhep.2018.03.019.","journal-title":"J Hepatol"},{"issue":"2","key":"4419_CR33","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/hep.29913","volume":"68","author":"JA Marrero","year":"2018","unstructured":"Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68(2):723\u201350. https:\/\/doi.org\/10.1002\/hep.29913.","journal-title":"Hepatology"},{"key":"4419_CR34","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.12464","author":"N Kokudo","year":"2015","unstructured":"Kokudo N, Hasegawa K, Akahane M, Igaki H, Izumi N, Ichida T, et al. Evidence-based clinical practice guidelines for hepatocellular carcinoma: the Japan Society of Hepatology 2013 update (3rd JSH-HCC guidelines). Hepatol Res. 2015. https:\/\/doi.org\/10.1111\/hepr.12464.","journal-title":"Hepatol Res"},{"issue":"1","key":"4419_CR35","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1148\/radiol.2241011262","volume":"224","author":"C Camm\u00e0","year":"2002","unstructured":"Camm\u00e0 C, Schepis F, Orlando A, Albanese M, Shahied L, Trevisani F, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology. 2002;224(1):47\u201354. https:\/\/doi.org\/10.1148\/radiol.2241011262.","journal-title":"Radiology"},{"issue":"4","key":"4419_CR36","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1159\/000012115","volume":"58","author":"T Okusaka","year":"2000","unstructured":"Okusaka T, Okada S, Ueno H, Ikeda M, Yoshimori M, Shimada K, et al. Evaluation of the therapeutic effect of transcatheter arterial embolization for hepatocellular carcinoma. Oncology. 2000;58(4):293\u20139. https:\/\/doi.org\/10.1159\/000012115.","journal-title":"Oncology"},{"key":"4419_CR37","doi-asserted-by":"publisher","first-page":"621","DOI":"10.2147\/JHC.S373112","volume":"9","author":"C Yang","year":"2022","unstructured":"Yang C, Luo YG, Yang HC, Yao ZH, Li X. Effects of early TACE refractoriness on survival in patients with hepatocellular carcinoma: A Real-World study. J Hepatocell Carcinoma. 2022;9:621\u201331. PMID: 35903756; PMCID: PMC9317376.","journal-title":"J Hepatocell Carcinoma"},{"issue":"3","key":"4419_CR38","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1002\/cam4.1330","volume":"7","author":"G Dong","year":"2018","unstructured":"Dong G, Zheng QD, Ma M, Wu SF, Zhang R, Yao RR, et al. Angiogenesis enhanced by treatment damage to hepatocellular carcinoma through the release of GDF15. Cancer Med. 2018;7(3):820\u201330. https:\/\/doi.org\/10.1002\/cam4.1330.","journal-title":"Cancer Med"},{"key":"4419_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-019-0771-8","volume":"19","author":"XT Fu","year":"2019","unstructured":"Fu XT, Song K, Zhou J, Shi YH, Liu WR, Shi GM, et al. Tumor-associated macrophages modulate resistance to oxaliplatin via inducing autophagy in hepatocellular carcinoma. Cancer Cell Int. 2019;19:71. https:\/\/doi.org\/10.1186\/s12935-019-0771-8.","journal-title":"Cancer Cell Int"},{"issue":"4","key":"4419_CR40","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1111\/j.1572-0241.2007.01712.x","volume":"103","author":"A Sergio","year":"2008","unstructured":"Sergio A, Cristofori C, Cardin R, Pivetta G, Ragazzi R, Baldan A, et al. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol. 2008;103(4):914\u201321. https:\/\/doi.org\/10.1111\/j.1572-0241.2007.01712.x.","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"4419_CR41","doi-asserted-by":"publisher","first-page":"925","DOI":"10.4143\/crt.2019.533","volume":"52","author":"M Xue","year":"2020","unstructured":"Xue M, Wu Y, Fan W, Guo J, Wei J, Wang H, et al. Prognostic value of TP53 mutation for transcatheter arterial chemoembolization failure\/refractoriness in HBV-related advanced hepatocellular carcinoma. Cancer Res Treat. 2020;52(3):925\u201337. https:\/\/doi.org\/10.4143\/crt.2019.533.","journal-title":"Cancer Res Treat"},{"issue":"20","key":"4419_CR42","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2019.09.142","volume":"7","author":"MY Pratama","year":"2019","unstructured":"Pratama MY, Pascut D, Massi MN, Tiribelli C. The role of MicroRNA in the resistance to treatment of hepatocellular carcinoma. Ann Transl Med. 2019;7(20):577. https:\/\/doi.org\/10.21037\/atm.2019.09.142.","journal-title":"Ann Transl Med"},{"issue":"1","key":"4419_CR43","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1159\/000430352","volume":"37","author":"L Cui","year":"2015","unstructured":"Cui L, Hu Y, Bai B, Zhang S. Serum miR-335 level is associated with the treatment response to trans-arterial chemoembolization and prognosis in patients with hepatocellular carcinoma. Cell Physiol Biochem. 2015;37(1):276\u201383. https:\/\/doi.org\/10.1159\/000430352.","journal-title":"Cell Physiol Biochem"},{"issue":"2","key":"4419_CR44","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.3892\/or.2015.4470","volume":"35","author":"J Tang","year":"2016","unstructured":"Tang J, Xiao L, Cui R, Li D, Zheng X, Zhu L, et al. CX3CL1 increases invasiveness and metastasis by promoting epithelial-to-mesenchymal transition through the TACE\/TGF-\u03b1\/EGFR pathway in hypoxic androgen-independent prostate cancer cells. Oncol Rep. 2016;35(2):1153\u201362. https:\/\/doi.org\/10.3892\/or.2015.4470.","journal-title":"Oncol Rep"},{"issue":"3","key":"4419_CR45","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1148\/radiol.2017170358","volume":"283","author":"LJ Savic","year":"2017","unstructured":"Savic LJ, Chapiro J, Geschwind JF. Science to practice: killing dormant cells-is targeting autophagy the key to complete tumor response in transarterial chemoembolization? Radiology. 2017;283(3):621\u20133. https:\/\/doi.org\/10.1148\/radiol.2017170358.","journal-title":"Radiology"},{"issue":"3","key":"4419_CR46","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1148\/rg.2017160122","volume":"37","author":"AS Moustafa","year":"2017","unstructured":"Moustafa AS, Abdel Aal AK, Ertel N, Saad N, DuBay D, Saddekni S. Chemoembolization of hepatocellular carcinoma with extrahepatic collateral blood supply: anatomic and technical considerations. Radiographics. 2017;37(3):963\u201377. https:\/\/doi.org\/10.1148\/rg.2017160122.","journal-title":"Radiographics"},{"issue":"1","key":"4419_CR47","first-page":"60","volume":"12","author":"S Takaki","year":"2020","unstructured":"Takaki S, Fukuhara T, Mori N, Tsuji K. High cholinesterase predicts tolerance to Sorafenib treatment and improved prognosis in patients with transarterial chemoembolization refractory intermediate stage hepatocellular carcinoma. Mol Clin Oncol. 2020;12(1):60\u20138. Epub 2019 Nov 18. PMID: 31814977; PMCID: PMC6888314.","journal-title":"Mol Clin Oncol"},{"key":"4419_CR48","doi-asserted-by":"publisher","unstructured":"European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908\u2009\u2013\u200943. https:\/\/doi.org\/10.1016\/j.jhep.2011.12.001. Erratum in: J Hepatol. 2012;56(6):1430. PMID: 22424438.","DOI":"10.1016\/j.jhep.2011.12.001"},{"issue":"10","key":"4419_CR49","doi-asserted-by":"publisher","first-page":"5650","DOI":"10.1007\/s00330-020-06911-9","volume":"30","author":"PH Kim","year":"2020","unstructured":"Kim PH, Gwon DI, Kim JW, Chu HH, Kim JH. The safety and efficacy of balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma refractory to conventional transcatheter arterial chemoembolization. Eur Radiol. 2020;30(10):5650\u201362. https:\/\/doi.org\/10.1007\/s00330-020-06911-9.","journal-title":"Eur Radiol"},{"key":"4419_CR50","doi-asserted-by":"publisher","first-page":"181","DOI":"10.2147\/JHC.S273929","volume":"7","author":"S Kobayashi","year":"2020","unstructured":"Kobayashi S, Tajiri K, Murayama A, Entani T, Futsukaichi Y, Nagata K, et al. Drug-eluting Bead-Transcatheter arterial chemoembolization for advanced hepatocellular carcinoma refractory to conventional Lipiodol-based transcatheter arterial chemoembolization. J Hepatocell Carcinoma. 2020;7:181\u20139. PMID: 33117752; PMCID: PMC7569043.","journal-title":"J Hepatocell Carcinoma"},{"issue":"1","key":"4419_CR51","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1080\/02656736.2020.1752400","volume":"37","author":"S Chen","year":"2020","unstructured":"Chen S, Shi M, Shen L, Qi H, Wan W, Cao F, et al. Microwave ablation versus sorafenib for intermediate-stage hepatocellular carcinoma with transcatheter arterial chemoembolization refractoriness: a propensity score matching analysis. Int J Hyperthermia. 2020;37(1):384\u201391. https:\/\/doi.org\/10.1080\/02656736.2020.1752400.","journal-title":"Int J Hyperthermia"},{"key":"4419_CR52","doi-asserted-by":"publisher","first-page":"3317","DOI":"10.2147\/CMAR.S305422","volume":"13","author":"X Xu","year":"2021","unstructured":"Xu X, Ding Y, Pan T, Gao F, Huang X, Sun Q. CT-Guided 125I brachytherapy in the treatment of hepatocellular carcinoma refractory to conventional transarterial chemoembolization: A pilot study. Cancer Manag Res. 2021;13:3317\u201326. PMID: 33883943; PMCID: PMC8055363.","journal-title":"Cancer Manag Res"},{"key":"4419_CR53","doi-asserted-by":"publisher","first-page":"7973","DOI":"10.2147\/CMAR.S332571","volume":"13","author":"KC Liu","year":"2021","unstructured":"Liu KC, Lv WF, Lu D, Hou CL, Xie J, Lu YH, et al. Initial experience of Drug-Eluting Bead-Transcatheter arterial chemoembolization after Lipiodol-Based transcatheter arterial chemoembolization failure for patients with advanced hepatocellular carcinoma. Cancer Manag Res. 2021;13:7973\u201380. PMID: 34703317; PMCID: PMC8541737.","journal-title":"Cancer Manag Res"},{"key":"4419_CR54","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/638747","volume":"2014","author":"O Tohyama","year":"2014","unstructured":"Tohyama O, Matsui J, Kodama K, Hata-Sugi N, Kimura T, Okamoto K, et al. Antitumor activity of lenvatinib (E7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res. 2014;2014:638747. https:\/\/doi.org\/10.1155\/2014\/638747.","journal-title":"J Thyroid Res"},{"issue":"6","key":"4419_CR55","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-021-01503-z","volume":"38","author":"N Une","year":"2021","unstructured":"Une N, Takano-Kasuya M, Kitamura N, Ohta M, Inose T, Kato C, et al. The anti-angiogenic agent lenvatinib induces tumor vessel normalization and enhances radiosensitivity in hepatocellular tumors. Med Oncol. 2021;38(6):60. https:\/\/doi.org\/10.1007\/s12032-021-01503-z.","journal-title":"Med Oncol"},{"key":"4419_CR56","doi-asserted-by":"publisher","first-page":"618206","DOI":"10.3389\/fonc.2021.618206","volume":"11","author":"J Mei","year":"2021","unstructured":"Mei J, Tang YH, Wei W, Shi M, Zheng L, Li SH, et al. Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus lenvatinib for advanced hepatocellular carcinoma. Front Oncol. 2021;11:618206. PMID: 33718175; PMCID: PMC7947809.","journal-title":"Front Oncol"},{"issue":"3","key":"4419_CR57","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.3892\/ol.2020.11758","volume":"20","author":"S Shimose","year":"2020","unstructured":"Shimose S, Kawaguchi T, Tanaka M, Iwamoto H, Miyazaki K, Moriyama E, et al. Lenvatinib prolongs the progression-free survival time of patients with intermediate-stage hepatocellular carcinoma refractory to transarterial chemoembolization: A multicenter cohort study using data mining analysis. Oncol Lett. 2020;20(3):2257\u201365. Epub 2020 Jun 19. PMID: 32782543; PMCID: PMC7400966.","journal-title":"Oncol Lett"},{"key":"4419_CR58","doi-asserted-by":"publisher","first-page":"9321","DOI":"10.2147\/CMAR.S223271","volume":"11","author":"Z Qiu","year":"2019","unstructured":"Qiu Z, Shen L, Chen S, Qi H, Cao F, Xie L, et al. Efficacy of apatinib in transcatheter arterial chemoembolization (TACE) refractory intermediate and Advanced-Stage hepatocellular carcinoma: A propensity score matching analysis. Cancer Manag Res. 2019;11:9321\u201330. PMID: 31802950; PMCID: PMC6830366.","journal-title":"Cancer Manag Res"},{"key":"4419_CR59","doi-asserted-by":"publisher","first-page":"576232","DOI":"10.3389\/fonc.2021.576232","volume":"11","author":"B Liang","year":"2021","unstructured":"Liang B, Makamure J, Shu S, Zhang L, Sun T, Zheng C. Treatment Response, Survival, and safety of transarterial chemoembolization with CalliSpheres\u00ae microspheres versus conventional transarterial chemoembolization in hepatocellular carcinoma: A Meta-Analysis. Front Oncol. 2021;11:576232. PMID: 33796448; PMCID: PMC8008112.","journal-title":"Front Oncol"},{"issue":"24","key":"4419_CR60","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13246172","volume":"13","author":"KI Bzeizi","year":"2021","unstructured":"Bzeizi KI, Arabi M, Jamshidi N, Albenmousa A, Sanai FM, Al-Hamoudi W, et al. Conventional transarterial chemoembolization versus drug-eluting beads in patients with hepatocellular carcinoma: a systematic review and meta-analysis. Cancers (Basel). 2021;13(24):6172. https:\/\/doi.org\/10.3390\/cancers13246172.","journal-title":"Cancers (Basel)"},{"issue":"21","key":"4419_CR61","doi-asserted-by":"publisher","first-page":"e15314","DOI":"10.1097\/MD.0000000000015314","volume":"98","author":"H Li","year":"2019","unstructured":"Li H, Wu F, Duan M, Zhang G. Drug-eluting bead transarterial chemoembolization (TACE) vs conventional TACE in treating hepatocellular carcinoma patients with multiple conventional TACE treatments history: A comparison of efficacy and safety. Med (Baltim). 2019;98(21):e15314. PMID: 31124925; PMCID: PMC6571239.","journal-title":"Med (Baltim)"},{"key":"4419_CR62","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1212577","volume":"14","author":"J Yang","year":"2023","unstructured":"Yang J, Guo Z, Song M, Pan Q, Zhao J, Huang Y, et al. Lenvatinib improves anti-PD-1 therapeutic efficacy by promoting vascular normalization via the NRP-1-PDGFR\u03b2 complex in hepatocellular carcinoma. Front Immunol. 2023;14:1212577. https:\/\/doi.org\/10.3389\/fimmu.2023.1212577.","journal-title":"Front Immunol"},{"key":"4419_CR63","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.actbio.2022.12.004","volume":"157","author":"Z Zheng","year":"2023","unstructured":"Zheng Z, Ma M, Han X, Li X, Huang J, Zhao Y, et al. Idarubicin-loaded biodegradable microspheres enhance sensitivity to anti-PD1 immunotherapy in transcatheter arterial chemoembolization of hepatocellular carcinoma. Acta Biomater. 2023;157:337\u201351. Epub 2022 Dec 10. PMID: 36509402.","journal-title":"Acta Biomater"},{"issue":"5","key":"4419_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2022.101893","volume":"46","author":"Q Shi","year":"2022","unstructured":"Shi Q, Liu J, Li T, Zhou C, Wang Y, Huang S, et al. Comparison of DEB-TACE and cTACE for the initial treatment of unresectable hepatocellular carcinoma beyond up-to-seven criteria: a single-center propensity score matching analysis. Clin Res Hepatol Gastroenterol. 2022;46(5):101893. https:\/\/doi.org\/10.1016\/j.clinre.2022.101893.","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"5","key":"4419_CR65","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1111\/jgh.12439","volume":"29","author":"K Huang","year":"2014","unstructured":"Huang K, Zhou Q, Wang R, Cheng D, Ma Y. Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma. J Gastroenterol Hepatol. 2014;29(5):920\u20135. https:\/\/doi.org\/10.1111\/jgh.12439.","journal-title":"J Gastroenterol Hepatol"},{"issue":"5","key":"4419_CR66","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1007\/s00432-022-04107-w","volume":"149","author":"W Fan","year":"2023","unstructured":"Fan W, Zhu B, Zheng X, Yue S, Lu M, Fan H, et al. Sorafenib plus drug-eluting bead transarterial chemoembolization for early intrahepatic stage-progressed advanced hepatocellular carcinoma refractory to conventional transarterial chemoembolization. J Cancer Res Clin Oncol. 2023;149(5):1873\u201382. https:\/\/doi.org\/10.1007\/s00432-022-04107-w.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"5","key":"4419_CR67","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1097\/NCC.0000000000000302","volume":"39","author":"H Blackburn","year":"2016","unstructured":"Blackburn H, West S. Management of postembolization syndrome following hepatic transarterial chemoembolization for primary or metastatic liver cancer. Cancer Nurs. 2016;39(5):E1\u201318. https:\/\/doi.org\/10.1097\/NCC.0000000000000302.","journal-title":"Cancer Nurs"},{"issue":"5","key":"4419_CR68","first-page":"1769","volume":"32","author":"C Sottani","year":"2012","unstructured":"Sottani C, Poggi G, Quaretti P, Regazzi M, Montagna B, Quaquarini E, et al. Serum pharmacokinetics in patients treated with transarterial chemoembolization (TACE) using two types of epirubicin-loaded microspheres. Anticancer Res. 2012;32(5):1769\u201374. PMID: 22593459.","journal-title":"Anticancer Res"},{"issue":"5","key":"4419_CR69","doi-asserted-by":"publisher","first-page":"374","DOI":"10.5582\/bst.2019.01153","volume":"13","author":"T Han","year":"2019","unstructured":"Han T, Yang X, Zhang Y, Li G, Liu L, Chen T, et al. The clinical safety and efficacy of conventional transcatheter arterial chemoembolization and drug-eluting beads-transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: A meta-analysis. Biosci Trends. 2019;13(5):374\u201381. Epub 2019 Oct 14. PMID: 31611486.","journal-title":"Biosci Trends"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04419-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-025-04419-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04419-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T10:00:39Z","timestamp":1763546439000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-025-04419-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4419"],"URL":"https:\/\/doi.org\/10.1186\/s12876-025-04419-4","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,19]]},"assertion":[{"value":"22 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was reviewed and approved by the Ethics Committee of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (Approval No.: S20230319). Due to the retrospective nature of the research, the Ethics Committee granted a waiver for the requirement of individual informed consent. All study procedures were conducted in strict accordance with the ethical principles outlined in the Declaration of Helsinki. Patient data were anonymized and handled confidentially to ensure privacy protection.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have read and approved the final version of the manuscript for submission. As a retrospective study utilizing anonymized data, no personally identifiable information was included in the analysis or presentation. The Ethics Committee confirmed that the publication of aggregated and anonymized data posed no ethical concerns regarding patient confidentiality.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"817"}}